ClaimsFiler urges investors with over $100,000 in losses to file lead plaintiff applications by September 28, 2026 in the securities class action against Capricor Therapeutics
Executive summary: ClaimsFiler notified investors holding losses exceeding $100,000 that they have until September 28, 2026 to submit lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. The lead plaintiff appointment will shape the direction of the litigation, affecting potential settlement size, legal expenses, and the timing of any financial resolution, which in turn influences Capricor’s near‑term financial position and sector perception.
Who is involved: Capricor Therapeutics (CAPR), ClaimsFiler, investors with >$100,000 losses, and law firms such as Glancy Prongay Wolke & Rotter LLP and Hagens Berman Sobol Shapiro LLP referenced in related alerts.
Likely next: Lead plaintiff motions will be filed before the September 28 deadline; the court will then consider the applications, after which the case may proceed to discovery, settlement discussions, or trial.
ClaimsFiler’s reminder highlights the approaching deadline for lead plaintiff selection in a lawsuit alleging that Capricor made misleading statements about its Deramiocel therapy and the integrity of clinical data. The deadline determines who will steer the litigation, influencing potential settlement amounts, legal costs, and the company’s near‑term financial outlook. While the alert itself is procedural, it underscores the ongoing litigation risk that could affect Capricor’s cash reserves and investor sentiment in the biotech sector.
What's next — scenarios
Base: lead plaintiff appointed, case proceeds to discovery (50%)
Capricor faces increased legal costs and a potential settlement in 2027 affecting cash reserves.
- Court approves lead plaintiff by October 15, 2026
- No settlement materializes by December 2026
Upside: case dismissed or settled favorably at low cost (30%)
Limited financial impact on Capricor, share price stabilizes.
- Court denies lead plaintiff appointment before September 28, 2026
- Early settlement reached before October 2026 with no material payment
Downside: judgment against Capricor with significant damages (20%)
Substantial financial liability, potential capital raise, adverse effect on biotech sector sentiment.
- Court finds liability and awards damages exceeding $50 million
- Capricor announces a capital raising transaction in Q1 2027
What to watch
- September 28, 2026: lead plaintiff application deadline for Capricor class action
- October 15, 2026: expected court hearing on lead plaintiff selection
- December 2026: potential settlement conference date
- Q1 2027: any capital raising announcement by Capricor
- FDA updates on the Deramiocel review extension timeline
Timeline
- — Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR (PR Newswire)
- — York Space Systems Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against York Space Systems, Inc. - YSS (PR Newswire)
- — Simply Good Foods Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Simply Good Foods Company - SMPL (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026: deadline for lead plaintiff applications in Capricor securities class action
- October 15, 2026 (approx): expected court hearing on lead plaintiff selection
- December 2026: potential settlement conference if lead plaintiff appointed
- Q1 2027: possible capital raising announcement if adverse judgment
Sectors affected
- biotechnology
- pharmaceuticals
- clinical trial services
Regulatory implications
- FDA review extension for Deramiocel (mentioned in Hagens Berman alert Sept 17 2026) may be examined as evidence in the Capricor securities class action
Historical parallels
- September 5, 2026 PR Newswire reminder about the same lead plaintiff deadline for Capricor (earlier alert)
- September 18, 2026 Glancy Prongay announcement that investors with losses have opportunity to lead the securities fraud lawsuit against Capricor
- September 17, 2026 Hagens Berman alert regarding FDA review extension for Deramiocel amid the ongoing class action
Key entities
Sources
- Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR — PR Newswire
- York Space Systems Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against York Space Systems, Inc. - YSS — PR Newswire
- Simply Good Foods Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against The Simply Good Foods Company - SMPL — PR Newswire
Related cases
- AEVEX investors warned of Oct 20 lead‑plaintiff deadline in securities class action
- Avis Budget Group faces critical deadline for lead plaintiff applications in securities fraud class action lawsuit
- ClaimsFiler alerts BBNX investors of approaching Nov 3 lead‑plaintiff deadline in securities class action
- Investors with over $100,000 in HDFC Bank losses must file lead plaintiff applications by Oct 13, 2026 in the ongoing securities class action
- ClaimsFiler warns Hims & Hers investors with over $100k losses that the lead plaintiff deadline in the securities class action is November 2, 2026
- ClaimsFiler reminds Simply Good Foods investors with over $100k losses of the October 13, 2026 lead plaintiff deadline in a securities class action suit